Welcome to the January 2011 edition of the ISPOR eBulletin. The ISPOR eBulletin provides updates of recent ISPOR activities and events. For detailed information on ISPOR activities, members are encouraged to see: www.ispor.org.
ISPOR Scientific Awards
The Society’s awards are designed to recognize outstanding achievements in pharmacoeconomics and outcomes research. The ISPOR scientific awards are:
- ISPOR Avedis Donabedian Lifetime Achievement Award
- ISPOR Bernie J. O’Brien New Investigator Award
- ISPOR Award for Excellence in Methodology in Pharmacoeconomics and Health Outcomes Research
- ISPOR Award for Excellence in Application of Pharmacoeconomics and Health Outcomes Research
These ISPOR awards will be presented at the ISPOR 16th Annual International Meeting in Baltimore, MD, USA, May 21-25, 2011. The ISPOR Awards Committee is now accepting nominations for all 4 awards. If you would like to nominate a candidate or yourself for one of the four awards, please send in the required nomination materials to: firstname.lastname@example.org by FRIDAY, FEBRUARY 11, 2011. Nomination requirements and detailed award descriptions can be found at the ISPOR website at:
ISPOR Scientific Achievement Awards »
ISPOR 16th Annual International Meeting, Baltimore, MD, USA
CALL FOR ABSTRACTS DEADLINE: JANUARY 13, 2011
The ISPOR 16th Annual International Meeting will be held May 21-25, 2011 at the Hilton Baltimore, Baltimore, MD, USA. For Plenary Session topics, sponsorship, exhibit, advertising and symposium opportunities, see:
ISPOR 16th Annual International Meeting »
ISPOR 3rd Latin America Conference, Mexico City, Mexico
CALL FOR ABSTRACTS DEADLINE: 17 MARCH 2011
The ISPOR 3rd Latin America Conference will be held 8-10 September, 2011 at the Hilton Mexico City Reforma, Mexico City, Mexico For preliminary program, sponsorship, exhibit, advertising and symposium opportunities, see:
ISPOR 3rd Latin America Conference »
ISPOR 14th Annual European Congress, Madrid, Spain
The ISPOR 14th Annual European Congress will be held 5-8 November, 2011 at the Hotel Auditórium Madrid, Madrid, Spain. For sponsorship, exhibit, advertising and symposium opportunities, see:
ISPOR 14th Annual European Congress »
ISPOR CONNECTIONS Volume 16, Issue 6 Now On-Line
ISPOR CONNECTIONS November/December 2010 is now available on-line.
ISPOR CONNECTIONS Volume 16, Issue 6 »
NEW! ISPOR CONNECTIONS World News
ISPOR CONNECTIONS now includes a new section, World News, which provides updates on health care policy, health technology assessment (HTA), and regulatory issues in countries around the world provided by the ISPOR Regional Chapters.
ISPOR CONNECTIONS »
Therapeutic and Diagnostic Devices Outcomes Research
Pre-order Now. Special Rate for ISPOR members
Therapeutic and Diagnostic Devices Outcomes Research »
ISPOR Asia Consortium Comments on draft China PE Guidelines
The ISPOR Asia Consortium commented on the draft China Guidelines for Pharmacoeconomics Evaluations (V8) developed by the China Society for Pharmacoeconomics and Outcomes Research (Chinese Pharmaceutical Association Pharmacoeconomics Committee). The comments are at: ISPOR COMMENTS on Health Policies. For Comments, see: Comments to China draft PE Guidelines. The draft China PE Guidelines (written in Chinese) were summarized by the ISPOR Asia Consortium and are at: Summary of draft China PE Guidelines
Eighth International Conference of the Polish Pharmacoeconomic Society
Critical issues in the health care systems in Poland and around the world were discussed during the 8th International Conference of the Polish Pharmacoeconomic Society organized by the ISPOR Poland Chapter. The conference, held on 2-3 December 2010 in Warsaw, Poland, featured key thought leaders from the field of medicine, economics and health care policies from Russia, Israel, China, and Hungary. For program highlights and photos, please see:
ISPOR Poland Regional Chapter »
ISPOR Conjoint Analysis Experimental Design Task Force (CAED TF)
The ISPOR Conjoint Analysis Experimental Design Task Force, chaired by F. Reed Johnson PhD, RTI Health Solutions, RTI International, recently approved by the ISPOR Board of Directors, will produce a conjoint analysis good research practices report that will include conjoint experimental design concepts, evaluate the advantages and disadvantages of the most recent alternative methods, and guide researchers on accessing and using available catalogues and software for constructing designs. For more details, please see:
ISPOR Conjoint Analysis Experimental Design Task Force »
ISPOR PRO Evidence of Content Validity Task Force
The ISPOR Patient Reported Outcomes Evidence of Content Validity Task Force has drafted their report (two papers) and will be available for comment by the ISPOR membership in mid-January 2011. The report addresses good research practices in the design of studies to gather evidence of content validity and good research practices for evaluating and documenting content validity.
ISPOR PRO Evidence of Content Validity Task Force »
TIP OF THE MONTH- ISPOR Good Outcomes Research Practices & Issues Index
The ISPOR Good Outcomes Research Practices & Issues Index provides consensus documents on key outcomes research methods. ISPOR’s role as a scientific educational organization is to assist in the development and dissemination of good practices in health outcomes research. With this goal to develop comprehensive good research practices, ISPOR convenes experts in outcomes research to develop guidance for researchers on contentious outcomes research methods. These peer-reviewed guidances, published in the Society’s scientific peer-reviewed journal, Value in Health.
ISPOR Good Outcomes Research Practices & Issues Index »
Online International Master’s Degree in Health Economics and Pharmacoeconomics
23 February 2011 – 5 December 2012
To provide specialised training in the economics and management of health services and pharmaceutical products (Health Economics and Pharmacoeconomics).
The concept of management in the health sector and the pharmaceutical sector is understood in the broadest sense of the term and includes public sector services, centres and services belonging to health care institutions at any level of care, pharmaceutical service providers, agencies for the evaluation of drugs and medical technologies, together with the pharmaceutical industry, pharmaceutical distributors, insurance companies and consultancy and advisory firms.
- Module 1. Economic Evaluation of Pharmaceuticals and Medical Technologies (1): Basic Concepts
- Module 2: Quantitative Techniques Applied to Health Service and Pharmacy Management
- Module 3: Economics and Policies of Pharmaceutical Financing
- Module 4: Economic Evaluation of Pharmaceuticals and Medical Technologies (2): Advances
- Module 5: Drug Management in Health Systems
- Module 7: Health Economics (2)
- Module 8: Term Paper
For more information, don’t hesitate to contact us at: email@example.com. You can also consult the web page at: www.idec.upf.edu/mesiol
Programme co-organised by: CRES-Research Center for Economy and Heath and IDEC-Universitat Pompeu Fabra